Clinical trial
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell…
NCT00128011 · International Vaccine Institute, Other · Completed
Key facts
| NCT number | NCT00128011 |
|---|---|
| Title | Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine |
| Official title | A Safety and Immunogenicity Study of a New Formulation of the Locally-Produced Bivalent Killed, Whole-Cell Oral Cholera Vaccine in Vietnamese Subjects |
| Lead sponsor | International Vaccine Institute, Other |
| Collaborators | National Institute of Hygiene and Epidemiology, Vietnam Göteborg University |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cholera |
| Intervention type | Biological |
| Interventions | killed oral cholera vaccine |
| Enrollment | 150 |
| Start date | May 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Aug 9, 2005 |
| Last update posted | Nov 10, 2006 |
| Countries | Vietnam |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: